Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02312258 · ClinicalTrials.gov registry record · Phase 3
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT02312258 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 706 participants.
The verdict
NCT02312258, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.
Interventions
- DRUG Placebo
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2015-04-09 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02312258
The ClinicalTrials.gov registry entry for NCT02312258 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02312258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02312258 about?
NCT02312258 is a clinical study titled "A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)". The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initia...
What is the current status of trial NCT02312258?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2015-04-09. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT02312258?
The interventions under investigation include: Placebo (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02312258?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.